• See Section 6 regarding identifying patients at moderate risk of hospitalization.
• The GDG concluded that nirmatrelvir-ritonavir represents a superior choice because it is easier to administer than a 3- day course of intravenous remdesivir.
• The conditional recommendation against represents the panel's view that remdesivir will represent a good choice only in those in whom nirmatrelvir-ritonavir is unavailable or involves problematic interactions, and even then only in a minority of such individuals.
• Remdesivir should be administered as soon as possible after onset of symptoms, ideally within 7 days

Practical info Given the conditional recommendation against using remdesivir for patients with non-severe COVID-19 at moderate risk of hospitalization, practical considerations were felt to be less relevant here. See practical info for use of remdevisir in patients with COVID-19 at high risk of hospitalization if needed.